Home/Pipeline/Prostate Cancer Pilot

Prostate Cancer Pilot

Prostate Cancer

PilotActive

Key Facts

Indication

Prostate Cancer

Phase

Pilot

Status

Active

Company

Lumito

About Lumito

Lumito is a pioneering diagnostics company commercializing a novel tissue imaging platform centered on upconverting nanoparticles (UCNPs), which offer ultra-sensitive detection without autofluorescence. Its core product, the SCIZYS system, enables high-accuracy quantification of biomarkers, targeting critical needs in precision oncology (e.g., HER2 low/ultralow expression) and translational research. The company is transitioning from development to early commercial engagements, leveraging a scalable 'Scan-as-a-Service' model and strategic partnerships to penetrate the growing digital pathology market.

View full company profile

Therapeutic Areas

Oncology Inflammatory Diseases

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active